Skip to content
BioSpace
PodcastScienceLife SciencesEnglish

BioSpace

NewThe untapped potential of drug repurposingNovember 19, 2026 · 19 min
Episodes
285
Released
daily
Latest episode
Nov 19, 2026

About the podcast

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Episodes 285

  1. The untapped potential of drug repurposing

    19 min

    In this episode of Denatured, I speak with Daniel Tillett, CEO of Racura Oncology and Sten Sörensen, CEO of Cereno Scientific. We explore why the FDA is now prioritizing drug repurposing, and what it will take …

  2. Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight

    23 min

    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history …

  3. Can we finally get ahead of drug shortages?

    21 min

    In this episode of Denatured, you'll hear from Christina Smolke, co-founder & CEO at Antheia and Kyle Pudenz, senior vice president and head of data & AI product at Cencora. We explore why drug shortages are …

  4. Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November

    24 min

    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a …

  5. Beyond the needle: The future of intratumoral therapy

    21 min

    In this episode of Denatured, you’ll hear from Lewis Bender, CEO at Intensity Therapeutics and Paul-Peter Tak, president, CEO and board director at Candel Therapeutics. We explore how intratumoral therapies …

  6. Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review

    23 min

    The majority of the large pharmas have now reported third quarter earnings—spoiler alert: Eli Lilly made more money than anyone expected. Plus, the FDA dropped another initiative aimed at accelerating rare …

  7. Stability, speed and strategy: Inside Australia’s early‑stage edge

    21 min

    In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has …

  8. Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025

    24 min

    Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and antibody-drug …

  9. Why investors are taking another look at kidney disease

    18 min

    In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and …

  10. Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners

    18 min

    China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run …

  11. Bonus: Q3 2026 Job Market Update

    16 min

    BioSpace Vice President Chantal Dresner and Angela Gabriel, content manager, life sciences careers, cover what happened in the biopharma job market during the third quarter. They discuss encouraging signs for …

  12. The decisions behind scientific progress

    11 min

    In this episode of Denatured, sponsored by Cytiva, Jennifer Smith-Parker speaks to Nicolas Pivet, VP & GM, Manufacturing & Digital Solutions at Cytiva. In this episode, we discuss how biopharma has long …

  13. J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback

    20 min

    Johnson & Johnson beat analyst expectations in the third quarter but left Wall Street wanting more; BMS dominated the news cycle on Monday with a Phase 3 win validating its $4.1 billion RayzeBio buy and mixed …

  14. Beyond equity: Why venture debt is reshaping European biotech

    23 min

    In this episode of Denatured, you’ll hear from Jennifer McMahon, partner at Seroba and Joey Mason, venture partner at Claret Capital. We dig into how venture debt buys time when equity can’t — and how Europe’s …

  15. Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

    24 min

    New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week …

  16. The race for access: How the FAIR Act could reclaim U.S. biotech leadership

    20 min

    In this episode of Denatured, you’ll hear from Max Bronstein, CEO of Aviva Strategies and Teresa Barnes, Chief Executive Warrior of PF Warriors. We dig into why U.S. patients are losing access to rare disease …

  17. AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll

    20 min

    Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed …

  18. How radioligand therapy is rewriting cancer care

    16 min

    In this episode of Denatured presented by Curium, Jennifer Smith-Parker speaks to Mike Patterson, CEO North America and Professor Sabine Brookman-May, vice president and head of Global Clinical Development. We …

  19. Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz

    21 min

    Novo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to turn things …

  20. When vision fades: Rethinking wet AMD and the durability gap

    22 min

    In this episode of Denatured, you’ll hear Philip Jacob Rosenfeld, professor of Ophthalmology at the University of Miami Health System and Bascom Palmer Eye Institute, and Wesley Jackson, chief science officer …

  21. FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival

    22 min

    The FDA held a public forum on Monday to discuss the future of psychedelic therapeutics, followed by a meeting on Wednesday regarding recommendations for reauthorizing the Prescription Drug User Fee Act the day …

  22. The supply chain fault lines of modern pharma

    36 min

    In this episode of Denatured, sponsored by SK Pharmteco, Jennifer Smith-Parker speaks to Arvind Singh, vice president and global head of supply chain. In this episode, we discuss how CDMOs are revamping …

  23. Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease

    20 min

    September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular …

  24. Breaking borders: Building biotech scale in Benelux

    19 min

    In this episode of Denatured, you’ll listen to Christina Takke, managing partner at V-Bio Ventures and Mariette van der Velden-Roesink, founding partner at Curie Capital. We examine why Benelux delivers …

  25. Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals

    20 min

    Novartis hits pause on several CAR T trials after three patient deaths, followed by Bristol Myers Squibb after separate safety signals; Revolution Medicines scores early FDA approval for groundbreaking …

  26. Fragile X at a turning point: Breaking through the clinical bottleneck

    19 min

    In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and …

  27. Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed

    23 min

    FDA extends its review of Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna tout positive data for their mRNA-based cancer …

  28. Rewriting the rules of CMV prevention

    20 min

    In this episode of Denatured, you’ll hear from Ian McGowan, Chief Medical Officer at Synklino and James Hunter, associate professor of transplantation at Oxford University. We explore transplantation and …

  29. Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more

    19 min

    Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients …

  30. The Italian inflection point: Clinical strength, culture and capital

    19 min

    In this episode of Denatured, you’ll hear from Diana Saraceni, founder and managing partner at Panakès Partners and Fabrizio Calisti, medical director at Angelini Ventures. We explore how Italy’s life sciences …

These are the latest 40 of 285 episodes. You’ll find older episodes in the podcast’s feed.

Is this your podcast?

Confirm it with an entry in your feed: you get a code here, add it as podcast:txt to the channel of your feed, and we check it. Your podcast is then shown as “verified” on SoundNode.

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.